



## MX<sub>1</sub>X<sub>2</sub>MX<sub>3</sub>EKWDX<sub>4</sub>NSSE

(SEQ ID NO:1),

wherein  $X_1$ ,  $X_2$ ,  $X_3$  and  $X_4$  are selected from codable amino acids, or a functionally equivalent fragment of said receptor, in a substantially pure form or a host cell transformed according to claim 14, with a test agent under conditions enabling the activation of said receptor, and detecting an increase or decrease in the receptor activity.

## REMARKS

The above amendments are made to delete multiple dependency in the claims. No new matter is contained in the amendment.

Please charge any fee deficiency or credit any overpayment to Deposit Account No. 50-1088.

Respectfully submitted,

CLARK & BRODY

Christopher W. Brody

Reg. No. 33,613

1750 K Street, NW, Suite 600

Washington, DC 20006 Telephone: 202-835-1753

Facsimile: 202-835-1755
Docket No.: 12020-0003
Date: December 8, 2000



MX<sub>1</sub>X<sub>2</sub>MX<sub>3</sub>EKWDX<sub>4</sub>NSSE



## MARKED-UP CLAIMS

Claim 11 (once amended) A host cell transformed with a polynucleotide molecule [according to] encoding an NPY-Y7 receptor or a functionally equivalent fragment thereof, wherein the encoded NPY-Y7 receptor is characterized by the N-terminal amino acid sequence:

Claim 22 (once amended) A method for detecting agonist or antagonist agents of an NPY-Y7 receptor, comprising contacting an NPY-Y7 receptor [according to] which is characterized by the N-terminal amino acid sequence:

wherein X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are selected from codable amino acids, or a functionally equivalent fragment of said receptor, in a substantially pure form [any one of claims 15-19] or a host cell transformed according to <u>claim 14</u> [any one of claims 11 to 14], with a test agent under conditions enabling the activation of said receptor, and detecting an increase or decrease in the receptor activity.

(SEQ ID NO:1),